Biohaven Ltd. (NASDAQ: BHVN) announced promising results from its ongoing Phase 1 study of BHV-1300, a potential first-in-class extracellular IgG degrader for autoimmune diseases. The study showed that weekly subcutaneous doses of 1000 mg led to rapid, deep, and sustained reductions in total immunoglobulin G (IgG) levels. Participants experienced reductions of up to 84%, with … Biohaven’s Potential First-in-Class Autoimmune Therapy BHV-1300 Cuts Total IgG by Over 80% Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.